Cite
Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study.
MLA
Uemura, Hirotsugu, et al. “Apalutamide for Metastatic, Castration‐sensitive Prostate Cancer in the Japanese Population: A Subgroup Analysis of the Randomized, Double‐blind, Placebo‐controlled Phase 3 TITAN Study.” International Journal of Urology, vol. 28, no. 3, Mar. 2021, pp. 280–87. EBSCOhost, https://doi.org/10.1111/iju.14447.
APA
Uemura, H., Arai, G., Uemura, H., Suzuki, H., Iijima, K., Nishimura, K., Fujii, K., Hatayama, T., Aoyama, J., Deprince, K., Lopez, G. A., McCarthy, S., Larsen, J. S., Li, J., & Chi, K. N. (2021). Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study. International Journal of Urology, 28(3), 280–287. https://doi.org/10.1111/iju.14447
Chicago
Uemura, Hirotsugu, Gaku Arai, Hiroji Uemura, Hiroyoshi Suzuki, Kazuyoshi Iijima, Kazuo Nishimura, Koji Fujii, et al. 2021. “Apalutamide for Metastatic, Castration‐sensitive Prostate Cancer in the Japanese Population: A Subgroup Analysis of the Randomized, Double‐blind, Placebo‐controlled Phase 3 TITAN Study.” International Journal of Urology 28 (3): 280–87. doi:10.1111/iju.14447.